These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35176502)

  • 1. Two-sample survival probability curves: A graphical approach for the analysis of time to event data in clinical trials.
    Castro-Pearson S; Le CT; Luo X
    Contemp Clin Trials; 2022 Apr; 115():106707. PubMed ID: 35176502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved precision in the analysis of randomized trials with survival outcomes, without assuming proportional hazards.
    Díaz I; Colantuoni E; Hanley DF; Rosenblum M
    Lifetime Data Anal; 2019 Jul; 25(3):439-468. PubMed ID: 29492746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials.
    Theilhaber J; Chiron M; Dreymann J; Bergstrom D; Pollard J
    BMC Bioinformatics; 2020 Jul; 21(1):333. PubMed ID: 32711453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kaplan-Meier curves for survivor causal effects with time-to-event outcomes.
    Chiba Y
    Clin Trials; 2013 Aug; 10(4):515-21. PubMed ID: 23610455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjusting for covariates in analysis based on restricted mean survival times.
    Zhong Y; Zhao O; Zhang B; Yao B
    Pharm Stat; 2022 Jan; 21(1):38-54. PubMed ID: 34231308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visualizing Time-Varying Effect in Survival Analysis: 5 Complementary Plots to Kaplan-Meier Curve.
    Huang Q; Tian C
    Oxid Med Cell Longev; 2022; 2022():3934901. PubMed ID: 35391933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of time to event outcomes in randomized controlled trials by generalized additive models.
    Argyropoulos C; Unruh ML
    PLoS One; 2015; 10(4):e0123784. PubMed ID: 25906075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A note on estimating treatment effect for time-to-event data in a literature-based meta-analysis.
    Hirooka T; Hamada C; Yoshimura I
    Methods Inf Med; 2009; 48(2):104-12. PubMed ID: 19283306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of gastric cancer survival: using an artificial hierarchical neural network.
    Amiri Z; Mohammad K; Mahmoudi M; Zeraati H; Fotouhi A
    Pak J Biol Sci; 2008 Apr; 11(8):1076-84. PubMed ID: 18819544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjusted survival curves with inverse probability weights.
    Cole SR; Hernán MA
    Comput Methods Programs Biomed; 2004 Jul; 75(1):45-9. PubMed ID: 15158046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of methods for estimating the attributable risk in the context of survival analysis.
    Gassama M; Bénichou J; Dartois L; Thiébaut AC
    BMC Med Res Methodol; 2017 Jan; 17(1):10. PubMed ID: 28114895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A flexible parametric survival model for fitting time to event data in clinical trials.
    Liao JJZ; Liu GF
    Pharm Stat; 2019 Oct; 18(5):555-567. PubMed ID: 31037824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing Kaplan-Meier curves with the probability of agreement.
    Stevens NT; Lu L
    Stat Med; 2020 Dec; 39(30):4621-4635. PubMed ID: 32969528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
    Weir IR; Trinquart L
    Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves.
    Liu N; Zhou Y; Lee JJ
    BMC Med Res Methodol; 2021 Jun; 21(1):111. PubMed ID: 34074267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.